Tissue-agnostic oncology is not replacing incidence-based definitions of rare cancer, but biomarker-driven therapies, genomic testing, and cross-tumor trial designs are changing how rare, actionable cancer populations are identified, studied, and treated.

Pheast Therapeutics' Roy Maute, Ph.D., discusses the scientific rationale behind CD24, the lessons carried forward from Forty Seven, the company’s clinical and combination strategy, and the broader potential of macrophage-directed therapies.

Cell and gene therapies are beginning to expand into rare oncology applications beyond hematologic malignancies, with recent advances in TIL therapy, TCR-engineered T cells, and early CAR-T studies highlighting both the promise of precision cellular immunotherapy and the development challenges of small patient populations, biomarker-defined eligibility, specialized manufacturing, and confirmatory evidence generation.

TriRx combines specialized liquid and semisolid manufacturing expertise, scalable processing, integrated filling and packaging, rigorous quality systems, and transparent partnership to help customers transfer and commercialize complex products reliably.

Healthcare AI cannot overcome sex and gender bias through more representative data alone; developers and health systems must also use subgroup testing, external validation, and continuous monitoring to demonstrate equitable performance.

Stem cell therapies are nearing broader clinical impact as advances in iPSCs, gene editing, bioengineering, and scalable manufacturing expand their therapeutic potential, although developers must still overcome safety, regulatory, and commercial-scale production challenges.